Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension

Although reliable assessments of safety and efficacy require a long-term randomized trial, the addition of sildenafil to background intravenous epoprostenol therapy appeared generally to be well tolerated in PAH patients.